Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 905

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 905
---
 CEO and our CFO are responsible for establishing
and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f). Management
conducted an assessment of the effectiveness of our internal control over financial reporting as of December 31, 2024. In making this
assessment, management used the criteria described in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring
Organizations of the Treadway Commission (“COSO”). Our management concluded that our internal controls over financial reporting
were effective based on those criteria, as of December 31, 2024.

Changes in Internal Control over Financial
Reporting

None.

Item 9B. Other Information

(b) Director and Officer
Trading Arrangements

None
of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading
arrangement (as such terms are defined in Item 408 of Regulation S-K) during the three months ended December 31, 2024.

Item 9C. Disclosure Regarding Foreign Jurisdictions
that Prevent Inspections

Not applicable.

67

PART III

Certain information required by Part III is omitted from this Annual
Report because the Company will file a definitive proxy statement within 120 days after the end of its fiscal year pursuant to Regulation 14A
(the Proxy Statement) for its annual meeting of stockholders, and certain information included in the Proxy Statement is incorporated
herein by reference.

Item 10. Directors, Executive Officers and
Corporate Governance

The information required by this Item 10 will be set forth in the
Proxy Statement and is incorporated in this Annual Report by reference.

Item 11. Executive Compensation

The information required by this item will be set forth in the Proxy Statement
and is incorporated in this Annual Report by reference.

Item 12. Security Ownership of Certain Beneficial
Owners and Management and Related Stockholder Matters

Equity Compensation Plan Information

The following table provides certain information
with respect to all of our compensation plans in effect as of December 31, 2024:

    Plan Category 
    (A) Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights  
    (B) Weighted Average Exercise Price of Outstanding Options, Warrants and Rights  
    (C) Number of Securities Remaining Available for Future Issuance Under Equity Compensation